negative control

ELA-14 negative control is an inactive peptide that serves as a negative control for ELA-14.

The compound is a negative control peptide for the Bax inhibitor peptides V5 and P5.

ZIP (SCRAMBLED) Acetate (ZIP (SCRAMBLED) Acetate (908012-18-0 Free Base)) is a scrambled peptide that can be used as a negative control for zeta inhibitory peptide (ZIP).

RLLFT-NH2 acetate is a reversed amino acid sequence negative control peptide for TFLLR-NH2.

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

Bradykinin analog nonapeptide. Reverse sequence of Bradykinin (Cat.No. 3004). Exhibits no significant kinin activity. Can be used as a negative control. Lande (1962) Retrobradykinin: a peptide with the reverse sequence of bradykinin. J.Org.Chem. 27 4558

Scrambled TRAP Fragment is a variant of the TRAP Fragment compound, characterized by its random amino acid sequence. It is typically employed as a negative control due to its similarity in composition to the active fragment.

Insulin β Chain Peptide (15-23), also referred to as INS, is an insulin-derived peptide specifically recognized by islet-associated T cells. The tetramer of Insulin β Chain Peptide (15-23) effectively stained the INS-reactive CTL clone G9C8; however, neither this tetramer nor the negative control tetramer (TUM) stained splenic CD8+ T cells from NOD or 8.3-TCRαβ transgenic NOD mice.

LL-37 scrambled peptide acetate, a scrambled version of the cathepsin antimicrobial peptide LL-37, is commonly used as a negative control in experiments involving the LL-37 peptide.

Tat-peptide 168-189, a cell-permeable, Tat-labeled fusion peptide derived from residues 168-189 of rat G3BP1, features the HIV Tat sequence at its least conserved terminus to enhance cellular uptake. It serves as the negative control for Tat-peptide 168-189 TFA, which promotes axon growth and neurite proliferation [1].

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand extensively used for research, therapy, and diagnosis of neoangiogenesis. It also serves as a negative control for cyclo(-RGDfK-), the RGD peptide, which modulates cell adhesion and is recognized by several integrin family members.

Compstatin control peptide acetate is a negative control of Compstatin. Compstatin is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

(S,S)-Z-FA-FMK is a cell-permeable, irreversible inhibitor of cathepsin B. This compound inhibits the production of IL-1α and IL-1β induced by LPS. Additionally, (S,S)-Z-FA-FMK serves as a negative control for caspase-1 and caspase-2 inhibitors due to the absence of an aspartic acid residue at the P1 position.

Prion Protein (106-126) (human) (scrambled) represents a disordered sequence of Prion Protein (106-126). It shares the same amino acid composition with the active segment of Prion Protein (106-126), but its sequence is randomly scrambled. This variant is commonly utilized as a negative control.

β Amyloid (1-42) (scrambled) TFA serves as a negative control for β-Amyloid (1-42), human TFA.

PTD (Antennapedia leader peptide) serves as the negative control for the TRAF6 inhibitory peptide DRQIKIWFQNRRMKWKK-RKIPTEDEY.

ReACp53 scrambled peptide serves as the negative control for ReACp53. It is applicable in ovarian cancer research.

mNLS-CPP-scramble serves as a negative control peptide for mNLS-CPP-WSTF. It shows potential for research into chronic inflammatory diseases, such as MASH and osteoarthritis.

Cyclo(Arg-Ala-Asp-D-Phe-Cys) is a cyclic RAD peptide serving as a positive or negative control for cyclo(Arg-Gly-Asp-D-Phe-Cys). It is utilized in multicolor ultrasound molecular imaging (USMI).

ReACp53scrambled peptide TFA serves as a negative control for ReACp53. It is applicable in ovarian cancer research.

SjDX5-271v serves as the negative control for SjDX5-271. The compound SjDX5-271 is a 3 kDa peptide that inhibits the TLR4/MyD88/NF-κB signaling pathway. Additionally, SjDX5-271 induces cellular polarization, alleviates liver inflammation, and protects mice from hepatic ischemia-reperfusion injury.